Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel
WARREN, N.J., PRNewswire/ -- Aquestive Therapeutics Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that Lori J. Braender, Esq. will join the company as Senior Vice President, General Counsel effective as of September 10.
"We are pleased to welcome Lori," said Keith J. Kendall, Chief Executive Officer of Aquestive Therapeutics. "With her knowledge and familiarity of the company, and the depth of her professional experience, Lori will be an important part of the leadership of Aquestive."
Braender joins Aquestive from a 35-year career at Day Pitney LLP, where she was most recently Chair of the Life Sciences Practice Group. In that role, she specialized in advising clients in pharmaceutical, biotechnology, medical device companies, hospitals and healthcare institutions on regulatory requirements, contractual arrangements, and other business considerations connected with life science and healthcare transactions.
Ms.Braender added, "I'm honored to join the Aquestive team. The company's unique business model and technology deliver meaningful solutions to patients, and I Iook forward to contributing the success of these efforts."
About Aquestive Therapeutics
These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials; the risks of delays in FDA approval of our drug candidates or failure to receive approval; the risks inherent in commercializing a new product (including technology risks, financial risks,market risks and implementation risks and regulatory limitations); development of our sales and marketing capabilities; the rate and degree of market acceptance of our product candidates; the success of any competing products; the size and growth of our product markets; the effectiveness and safety of our product candidates; risks associated with intellectual property rights and infringement; unexpected patent developments; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Registration Statement on Form S-1 declared effective by the SEC on July 24, 2018. As with any pharmaceutical product candidate underdevelopment, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We assume no obligation to update our forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required under applicable law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-names-lori-j-braender-esq-as-senior-vice-president-general-counsel-300710098.html
SOURCE Aquestive Therapeutics
Company Codes: NASDAQ-NMS:AQST